No Data
No Data
Zhixiang Jintai (688443.SH): 25 million shares of restricted shares will be unlocked on September 27th.
On September 19, Gelonghui announced that the total number of stocks listed this time for Zhixiang Jintai (688443.SH) is 25 million shares. The listing date for stocks is September 27, 2024.
Chongqing Genrix Biopharmaceutical Chair Proposes Up to 40-Million-Yuan Share Buyback
Express News | Zhi Xiang Jin Tai: The chairman proposed to repurchase shares in the range of 20 million yuan to 40 million yuan.
Zhixiang Jintai (688443): Selliteqi monoclonal antibody approved for listing, core products progressing smoothly.
2024 first-half performance: Sartuzumab vedotin was approved in August 2024, and the company had no main business income in the first half of 2024, only a small amount of other business income of 0.0127 million yuan from land leasing; sales expenses 3697.
Zhi Xiang Jin Tai (688443): Commercialization of IL-17 is underway, and the research pipeline is steadily progressing.
Report Summary: IL-17 monoclonal antibody has recently been approved for marketing, officially starting commercialization and actively promoting access and market expansion. It is expected to empower early commercialization, with a rich pipeline of research and continuous efficient clinical progress, promising long-term performance growth. Investment
2024 Semi-Annual Report Summary
No Data
No Data